138 related articles for article (PubMed ID: 18438341)
1. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
Berezhnaya NM; Vinnichuk YD; Belova OB
Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
Belova OB; Vinnichuk UD; Shlakhovenko VA; Berezhnaya NM
Exp Oncol; 2007 Dec; 29(4):272-6. PubMed ID: 18199982
[TBL] [Abstract][Full Text] [Related]
3. Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin.
Berezhnaya NM; Kovalchuk EV; Vinnichuk YD; Spivak SI; Belova OB
Eksp Onkol; 2004 Mar; 26(1):63-6. PubMed ID: 15112582
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
[TBL] [Abstract][Full Text] [Related]
5. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study.
Berezhnaya NM; Vinnichuk UD; Konovalenko VF; Vorobjova LI; Belova OB; Proskurnia LA
Exp Oncol; 2005 Dec; 27(4):303-7. PubMed ID: 16404351
[TBL] [Abstract][Full Text] [Related]
7. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
9. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
Da Costa ML; Redmond HP; Bouchier-Hayes DJ
J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
11. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
Bereznaya NM; Kirnasovskaya EA; Vinnichuk YD; Belova OB; Lukyanova NY
Exp Oncol; 2008 Dec; 30(4):295-9. PubMed ID: 19112427
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
18. Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action.
Berezhnaya NM; Belova OB; Vinnichuk YD; Tarutinov VI
Exp Oncol; 2009 Dec; 31(4):242-5. PubMed ID: 20010527
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2-mediated suppression of murine lymphokine-activated killer cell activity generated from tumor-bearing hosts by interferon-gamma.
Nakajima I; Chu TM
Mol Biother; 1990 Dec; 2(4):228-32. PubMed ID: 2126942
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
